Risk of carpal tunnel syndrome is higher in breast cancer patients given the drug exemestane than in those treated with tamoxifen, according to an international study in the Lancet Oncology.
Researchers looked at data from a study involving 4,700 women with early stage breast cancer.
Carpal tunnel syndrome was reported in 2.8% of 2,319 patients taking exemestane compared with 0.6% of 2,338 taking tamoxifen.
Those who developed the syndrome suffered it for six months on average.
- Mieog J.S.D. et al. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2—3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. The Lancet Oncology, Early Online Publication, 20 January 2012.